Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,109 | 549 | 3,508 |
| Samples | 1,301 | 252 | 1,033 |
| Peptides | 1,076 | 176 | 935 |
Function
SCN3A · Sodium voltage-gated channel alpha subunit 3
Voltage-gated sodium channels are transmembrane glycoprotein complexes composed of a large alpha subunit with 24 transmembrane domains and one or more regulatory beta subunits. They are responsible for the generation and propagation of action potentials in neurons and muscle. This gene encodes one member of the sodium channel alpha subunit gene family, and is found in a cluster of five alpha subunit genes on chromosome 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000283254 | Q9NY46-3 | 1,498 | 1,023 |
| ENST00000639244 | A0A1W2PRD1* | 1,306 | 946 |
| ENST00000409101 | Q9NY46-2 | 1,305 | 941 |
Gene Properties
Recurrent Mutations
All 1022 amino-acid changes on canonical ENST00000283254 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SCN3A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SCN3A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 34/210 16% | 194/1899 10% |
| Acute Myeloid Leukemia | 8/90 9% | 0/0 0% |
| Endometrial Carcinoma | 10/42 24% | 43/612 7% |
| Non-Small Cell Lung Carcinoma | 44/304 14% | 87/1390 6% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Glioblastoma | 6/98 6% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 41/810 5% |
| Other Solid Cancers | 10/94 11% | 73/1515 5% |
| Colorectal Carcinoma | 31/143 22% | 130/3239 4% |
| Gastric Carcinoma | 7/74 9% | 70/1809 4% |
| Bladder Carcinoma | 4/58 7% | 29/956 3% |
| Hodgkins Lymphoma | 0/16 0% | 4/122 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 22/752 3% |
| Neuroendocrine Tumour | 11/154 7% | 9/577 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Cervical Carcinoma | 0/35 0% | 11/422 3% |
| Head and Neck Carcinoma | 3/85 4% | 35/1574 2% |
| Mesothelioma | 2/62 3% | 3/165 2% |
| Burkitts Lymphoma | 5/32 16% | 0/196 0% |
| Ovarian Carcinoma | 5/109 5% | 19/998 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Breast Carcinoma | 17/144 12% | 44/3264 1% |
| Glioma | 4/52 8% | 35/2127 2% |
| Esophageal Carcinoma | 2/23 9% | 12/769 2% |
| Adrenocortical Carcinoma | 0/3 0% | 2/112 2% |
| Hepatocellular Carcinoma | 0/46 0% | 34/2210 2% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 37/2550 1% |
| Rhabdomyosarcoma | 1/33 3% | 2/171 1% |
| Plasma Cell Myeloma | 3/44 7% | 2/305 1% |
| Other Sarcomas | 4/69 6% | 7/699 1% |
Mutation Distribution
Where SCN3A is mutated · all tissues, split by cell line vs tissue
How many mutations in SCN3A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,109 mutations in SCN3A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|